We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 46% below its sector, cheaper than its peers on earnings.
Vaishali Pharma Limited functions as a pharmaceutical enterprise, conducting its business both within India and across global markets. The company's extensive product portfolio encompasses Active Pharmaceutical Ingredients (APIs), covering a broad spectrum of therapeutic areas. These include substances used in the treatment of bacterial infections (antibiotics), digestive issues (anti-ulcer), pain and inflammation (anti-inflammatory, analgesic, antipyretic), malaria, cardiovascular conditions, diabetes, common cold and allergies, diarrheal and parasitic diseases, viral infections, epilepsy, asthma, fungal infections, blood clot prevention (anti-platelet agents), muscle relaxation, and parasitic worm infections (anti-helmintics). Beyond these, Vaishali Pharma also supplies excipients, topical steroids, corticosteroids, and various enzymes. In addition to APIs, the company manufactures and distributes a diverse range of finished pharmaceutical formulations. These include prepared medications for bacterial infections, anti-platelet actions, laxative effects, digestive/enzyme support, asthma, malaria, cold/allergy/viral symptoms, psychotic disorders, fungal infections, pain/inflammation, diabetes, cardiac ailments, vitamin deficiencies, and topical steroid/corticosteroid applications, among other general formulations. Furthermore, its offerings extend to specialized segments such as veterinary pharmaceuticals, nutraceuticals, oncology products, herbal remedies, and surgical supplies. Established in 1989, the company maintains its corporate headquarters in Mumbai, India.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save VAISHALI.NS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.